Psychopharmacotherapy of Depressive Disorders-Reference-Cited by-同舟云学术

Psychopharmacotherapy of Depressive Disorders

Published:2021 Issue: Volume: Page:1-41
ISSN:
Container-title:NeuroPsychopharmacotherapy
language:
Short-container-title:

Author:

Kavakbasi Erhan,Baune Bernhard T.

Publisher

Springer International Publishing

Link

https://link.springer.com/content/pdf/10.1007/978-3-319-56015-1_427-1

Reference100 articles.

1. Aaronson ST, et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatr. American Psychiatric Association. 2017;174(7):640–8. https://doi.org/10.1176/appi.ajp.2017.16010034.

2. Adli M, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci. 2005:387–400. https://doi.org/10.1007/s00406-005-0579-5.

3. Adli M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry. © Georg Thieme Verlag KG Stuttgart New York. 2008;41(6):252–7. https://doi.org/10.1055/s-0028-1083819.

4. Adli M, et al. How effective is algorithm-guided treatment for depressed inpatients? results from the randomized controlled multicenter German algorithm project 3 trial. Int J Neuropsychopharmacol. Oxford University Press. 2017;20(9):721–30. https://doi.org/10.1093/ijnp/pyx043.

5. Altinay M, Karne H, Anand A. Administration of sub-anesthetic dose of ketamine and electroconvulsive treatment on alternate week days in patients with treatment resistant depression: a double blind placebo controlled trial. Psychopharmacol Bull. 2019;49(1):8–16. NLM (Medline). Available at: /pmc/articles/PMC6386425/?report=abstract. Accessed 8 July 2020